What is ALKS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 7.21B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALKS?

P/E (TTM) is 104.58 and 52-week range is $27.00 to $55.67 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALKS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALKS?

The company profile lists revenue (TTM) near $1.61B, net income (TTM) near $64M, EPS (TTM) near $0.38 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Alkermes Plc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Dublin, Dublin, IE, 167.8M shares outstanding, ISIN IE00B56GVS15 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Alkermes Plc

$ALKS

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.

Employees

2,050

Website

www.alkermes.com/

IPO

1991-07-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

IE00B56GVS15

Headquarters

Dublin, Dublin, IE

Shares outstanding

167.8M

NAICS sector

Manufacturing

Institutional ownership

107.82%

Browse other companiesFree AI scores and summaries for more stocks